简介:摘要目的观察米力农治疗慢性心力衰竭伴缓慢性心律失常患者的临床疗效及安全性。方法将80例慢性心力衰竭合并缓慢性心律失常的患者随机分为两组,常规治疗组予以常规抗心衰治疗,米力农干预组在常规治疗基础上加用米力农。观察两组治疗前后临床心功能NYHA分级、B型利钠肽(BNP)水平、左室射血分数(EF)、左室舒张末期内径(LVEDD)、24小时动态心电图指标平均心室率、室性心律失常、长RR间期。结果两组患者治疗后心功能分级、B型利钠肽(BNP)水平、左室射血分数(EF)均有显著改善,治疗前后差异具有统计学意义(P<0.05);治疗组较对照组患者BNP下降水平、LVEF升高幅度更显著,差异具有统计学意义(P<0.05);但两组LVEDD治疗前后改善不明显,无统计学差异(P>0.05)。两组治疗前后平均心率、室性心律失常、长RR间期事件无明显增加,组间及组内差异无统计学意义(P>0.05)。结论在常规抗心衰治疗基础上短期使用米力农治疗慢性心力衰竭伴缓慢性心律失常,临床疗效显著且安全可靠。
简介: 【摘要】 目的 探讨双腔心脏起搏器对缓慢性心律失常患者心功能的影响。方法 110例缓慢性心律失常患者, 根据治疗方案不同分为对照组和观察组, 每组 55例。对照组患者采用单腔心脏起搏器治疗, 观察组患者采用双腔心脏起搏器治疗。比较两组患者疗效、不良反应发生情况及治疗后左室射血分数( LVEF)、心脏指数、 5 min步行距离。结果 治疗后, 观察组患者心脏指数、 LVEF以及 5 min步行距离分别为( 3.36±0.56) L/( min·m2)、( 39.22±5.11) %、( 518.56±41.34) m, 均优于对照组的( 3.10±0.55) L/( min·m2)、( 35.26±5.06) %、( 500.56±40.67) m, 差异具有统计学意义( P<0.05)。观察组患者总有效率为 98.18%, 高于对照组的 85.45%, 差异具有统计学意义( P<0.05)。两组患者不良反应发生率比较差异无统计学意义( P>0.05)。结论 对缓慢性心律失常患者应用双腔心脏起搏器治疗对患者心功能影响小, 整体治疗效果符合临床需求, 安全性高, 值得推广。 【关键词】 缓慢性心律失常 ;双腔心脏起搏器 ;心功能 ;影响 [Abstract] Objective To investigate the effect of dual chamber pacemaker on cardiac function in patients with bradycardia. Methods 110 patients with bradycardia and chronic arrhythmia were divided into control group and observation group according to different treatment plans, 55 cases in each group. Patients in the control group were treated with single chamber pacemaker, while patients in the observation group were treated with dual chamber pacemaker. The effects, adverse reactions, left ventricular ejection fraction (LVEF), cardiac index and 5-min walking distance were compared between the two groups. Results after treatment, the heart index, LVEF and 5-min walking distance of the patients in the observation group were (3.36 ± 0.56) l / (min · m2), (39.22 ± 5.11)% and (518.56 ± 41.34) m, respectively, which were superior to those in the control group (3.10 ± 0.55) L / (min · m2), (35.26 ± 5.06)% and (500.56 ± 40.67) m, with statistical significance (P < 0.05). The total effective rate of the observation group was 98.18%, higher than 85.45% of the control group, the difference was statistically significant (P < 0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P > 0.05). Conclusion the application of dual chamber pacemaker in patients with bradycardia and chronic arrhythmia has little effect on cardiac function, and the overall treatment effect is in line with clinical needs, with high safety, which is worth promoting.
简介:【摘要】 目的:探讨急性心肌梗死合并缓慢心律失常患者采取心脏临时起搏器的价值。方法:选取本院在2020年1月-2021年1月期间收治的急性心肌梗死合并缓慢心律失常患者(n=46)为本次研究对象。 采取随机数字表法分为参考组(n=23)及实验组(n=23),其中参考组采取常规治疗,实验组采取心脏临时起搏器干预。对比两组抢救效果。结果:实验组抢救成功率高于参考组(P<0.05)。实验组并发症发生率低于参考组(P<0.05)。结论:在急性心肌梗死合并缓慢心律失常患者抢救中采取心脏临时起搏器,能够显著提升患者的抢救成功率,同时可减少并发症产生,其临床应用价值可观。